This trial will compare the standard of care for second line treatment of metastatic colorectal cancer (mCRC) against different combinations of NIS793 and other investigational drugs. The goal is to see if this new approach is more effective and has fewer side effects.
2 Primary · 26 Secondary · Reporting Duration: Upto approximately 12 months
266 Total Participants · 5 Treatment Groups
Primary Treatment: Bevacizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: